Fanpu Ji

@ElonMuskNews47 Yes

@YeeHuiYeo1 @BrennanSpiegel @LiranOmer @ItaiDanovitch @JuDongYang1 恭喜毅辉兄弟！👍👍

Extremely honored and humbled! Grateful to my mentor @BrennanSpiegel @LiranOmer @ItaiDanovitch @JuDongYang1 Dr. Almario whose guidance and support made this possible. Looking forward to the career ahead!

@wonglaihung @CUHKMedicine @CUHKGI @UMichMedSchool @MichiganLiver @ebtapper @GraceSu15 @VWSWong @TerryYip12 @HenryLYChan @norahterrault 👍👏

Truly privileged to be here #AnnArbor in person on behalf of @CUHKMedicine @CUHKGI to celebrate with the big Lok's Family at @UMichMedSchool @MichiganLiver #BestMentorEver 🥰🥰👩🏻‍🏫👩🏻‍🏫#BestAcademicGrandMaEver 😄😄👵🏻👵🏻

🌟New study shows #Sinomenine (SIN), a natural alkaloid, protects against #fibrosis in mice & #HSCs by blocking TGF-β/SMAD & c-JUN signaling. 📉 ↓ Collagen & α-SMA 🛡️ ↓ Liver injury & inflammation 🚀 SIN = a promising anti-fibrotic therapy! shorturl.at/2hSNt

@A_DAlessioMD @EASLedu @EASLnews 👍👍👍👍

The calm before the storm... 🎙️ What a pleasure to share the stage with a stellar panel to talk about the challenges of ICI in HCC patients with impaired liver function at #easl25 @EASLedu @EASLnews

📢New in #Hepatology: AI model (preoperative CT & clinical data) predicts #HCC recurrence. ✅Predicts recurrence 1–5 years out with AUROC ~0.8 ✅Beats microvascular invasion & multiple clinical risk scores 🔗shorturl.at/DR8Ia #LiverCancer #DeepLearning @WK_Seto @RexWHHui

📉 New insights into #MASLD-#cACLD 1️⃣ First #decompensation ↑ liver-related death risk 18.9-fold ☠️ 2️⃣ Further decompensation adds 1.52-fold risk ⚠️ 3️⃣ Ascites is the most common event 4️⃣ #HCC worsens outcomes🧬 5️⃣ High extrahepatic death burden due to metabolic risk ❤️🧠

📢New in @JCSM_cachexia : Combining fat distribution + BMI redefines obesity. Centripetal obesity indicators outperformed BMI alone in predicting all-cause mortality. It’s time to rethink how we define and evaluate #obesity in clinical practice. 🔗shorturl.at/gY8YB

How does your diet affect liver health? 🍽️High branched-chain amino acids (BCAAs) intake ↑ #MASLD risk 🟢Higher arginine intake ↓ risk significantly 💪Balanced amino acid profiles are key for prevention #NutritionScience #AminoAcids #MetabolicHealth 🔗shorturl.at/r1PRG

@BrennanSpiegel Big congratulations Dr. Spiegel! Great work!

🚨 Just published: My new paper, “Gut-derived serotonin as a molecular mediator of gravity management.” Serotonin helps us stand, balance, circulate blood, adapt to gravity—thanks to the gut microbiome. Disruptions may underlie POTS, IBS, and more. Read: neurogastrolatamreviews.com/frame_eng.php?…

🧬Can #geneediting fight #liverfibrosis? #CRISPR & other tools precisely target fibrosis pathways, offering hope for liver disease & cancer. 🎯 Precise & powerful ⚠️ Challenges remain 🚀 #Precisionmedicine for liver disease is on the horizon! shorturl.at/64zzA

🧫 Mesenchymal #stemcells (#MSCs) suppress pro-fibrotic intrahepatic B cells via exosomes, easing #liverfibrosis by blocking MAPK/NF-κB pathways 📉 ↓ B cell activation 📉 ↓ Inflammation & collagen 🧬 B cells = new therapeutic target shorturl.at/Cjtfe

🔥Myocardial infarction fuels #MASH progression by: ✅Triggering immune-inflammatory cascade ✅Inducing periostin expression 🧬 💔 Heart attacks worsen liver fibrosis Key link between heart & liver health! 🩺 #MI #InflammationResearch #Periostin 🔗shorturl.at/FIqqk

Waist-based indices > BMI for predicting both #MASLD and fracture risk. 🤔The relationship between #Sarcopenia and MASLD remains unclear. 😯Finding better BMI alternatives to better understand how adiposity drives liver and muscle disease. @JCSMJournal 🔗shorturl.at/fmZuv

🚨 Vitamin D isn't just for bones🦴—it may reduce liver inflammation & fibrosis! 🟡 Low vitamin D = worse liver outcomes 🧪 TXNIP knockout = more fibrosis 🎯 Vitamin D/TXNIP axis = a promising therapeutic target! #LiverDisease #Fibrosis #VitaminD #TXNIP 👉🏻shorturl.at/PTGJc

#Atezolizumab + #Bevacizumab vs #HCC 🔬 #scRNAseq unveils two response patterns: immune-mediated & angiogenesis-linked 🔍 IDs key cells/pathways driving primary resistance 🌟 Provides framework for patient stratification & overcoming treatment resistance 🔗shorturl.at/0FL47

🧬 Early #MASLD fights #HCC 🐭 In mouse models, steatosis inhibits HCC development ⚙️ Activates #Yap/Taz, boosting hepatocyte fitness 💥 Healthy #hepatocytes eliminate tumor-initiating cells via cell competition (not toxicity) 👉shorturl.at/o7zJp

@ArndtVogel @TheLancet @myESMO @EASLedu @ILCAnews ✊

Nivolumab plus ipilimumab vs lenvatinib or sorafenib as first-line treatment for HCC @TheLancet doi.org/10.1016/S0140-… 🔎CheckMate 9DW 👉mOS 23·7 vs 20·6 mo 👉ORR 36 vs 13% 👉Consistent efficacy in ALBI 1 and 2 🧐Great new option for 1st line HCC @myESMO @EASLedu @ILCAnews #livertwitter

@RajivJalan1 @drgautammehta 👍👍

Incredible effort by @drgautammehta and the team in completing the recruitment for this amazing study. Has the potential to revolutionise management of patients suffering from problems drinking.

🔬 New Study on #MASLD! 1️⃣AI-based FibroNest reveals 327 hepatic fiber phenotypes 🧬 2️⃣ #FibroPC4 linked to gene signature predicting #HCC development 📊 3️⃣ #IGFBP-7 transforms HSCs into HCC phenotype💥 shorturl.at/ZiZL5